-
Product Insights
Aspergillosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Aspergillosis - Drugs In Development, 2023’, provides an overview of the Aspergillosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Allergic Bronchopulmonary Aspergillosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Bronchopulmonary Aspergillosis - Drugs In Development, 2023’, provides an overview of the Allergic Bronchopulmonary Aspergillosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Bronchopulmonary Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Systemic Aspergillosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic Aspergillosis - Drugs In Development, 2023’, provides an overview of the Systemic Aspergillosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...